Summary Slide Presentation Principles of HIV drug resistance for clinical management in South Africa Stott K, Michel J, de Oliveira T. Principles of HIV.

Slides:



Advertisements
Similar presentations
CD4 and VL Monitoring: Research and Development needs and Policy implications Monitoring ART session XVIII IAC Vienna 2010 Prof Charles Gilks UNAIDS India.
Advertisements

Spending on ART by Provinces in South Africa: trends, cost drivers, (in)efficiencies and sustainability Simelela, N., Sipho, S., Sozi, C., Damisoni, H.,
Affordable Resistance Testing for Africa (ART-A)
MSF Experience on Use of HIV Viral Load testing in Myanmar.
THE ROLE OF PLHIV IN COMMUNITY ART SERVICE DELIVERY DR. STEPHEN WATITI (MB. CH.B)
World Health Organization TB Case Definitions
Dental Management of the Patient With HIV/AIDS; Current Concepts: 2002 Introduction Pennsylvania Mid-Atlantic AIDS Education and Training Center Introduction.
Trends in Antiretroviral Drugs Prescribing at Public Health Facilities in Ethiopia: Compliance to Treatment Guidelines Authors: Hailu Tadeg and Negussu.
Treatment challenges of 2 nd /3 rd line HIV/AIDS, hepatitis-C in Seychelles BY DR LOUINE MOREL.
Salvage Antiretroviral Therapy Guiding Principles, Strategies and the Role of Resistance Testing.
Possible solution: Change testing & care for patients in TB treatment Old system TB patient treated at TB center Referred to VCT center for HIV testing.
Evaluating Cost Gavin Steel, Jude Nwokike, Mohan P. Joshi & Mupela Ntengu Development and Implementation of a Multi-Method Medication Adherence Assessment.
Summary Slide Presentation Primary drug resistance in South Africa - data from 10 years of surveys Manasa J, Katzenstein D, Cassol S, Newell ML, de Oliveira.
World Hepatitis Day 2013, 29 th July Establishing a framework for better data collection and surveillance of Hepatitis in South Africa N. Prabdial-Sing.
Implementing antiretroviral therapy rollout to strengthen the health care system Dr Olive Shisana Human sciences Research Council.
What do models estimate to be the impacts on HIV incidence of various percentages of people with HIV on ART ? National AIDS Trust Treatment as Prevention.
Southern African HIV Clinicians Society's strategic imperatives Dr Francesca Conradie President of the SAHCS.
Summary Slide Presentation Are subtype differences important in HIV drug resistance? Lessells RJ, Katzenstein DK, de Oliveira T. Are subtype differences.
Challenges in monitoring ARV therapy A clinical and public health view of the issues involved Charlie Gilks SRM team, HIV department.
1 ARV Drug Resistance HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Experience with common basket for ARV procurement Tanzania Emma Lekashingo Msuya.
PRESENTATION: PORTFOLIO COMMITTEES ON CORRECTIONAL SERVICES AND HEALTH PROVISION OF HEALTH CARE WITHIN CORRECTIONAL CENTRES 1.
The WHO HIV Drug Resistance Strategy Presented by Dr. Don Sutherland Prepared by: Dr. Don Sutherland Dr Silvia Bertagnolio Dr Diane Bennett HIV Drug Resistance.
ZIMBABWE AIDS CARE FOUNDATION NEWLANDS CLINIC Virological Outcomes in Adult Patients on Second Line ART, at Newlands Clinic Dr S. Bote.
HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System The United Kingdom provides excellent access and quality of.
Resistance Mutations Before and After Tenofovir Regimen Failure in HIV-1 Infected Patients. £ Background: Except for the K65R mutation, little is known.
Are Patients on HAART in Uganda experiencing less treatment failure than earlier anticipated? A case study of Mbarara JCRC HAART Clinic.
Sub module 1 Introduction to HIV care and ART recording and reporting system.
Washington D.C., USA, July 2012www.aids2012.org Changing Patterns of NRTI and PI Resistance Mutations Between 2006 and 2011 in ART experienced SA.
1 Assisting PLWHAs Returning to Mexico and other Latin American Countries: A Pilot Project Oscar Gonzalez, PhD Texas/Oklahoma AETC Tracy Tessmann, MA Texas/Oklahoma.
1 Adherence to ARV Therapy and Resistance HAIVN Havard Medical School AIDS Initiative in Vietnam.
Antiretroviral treatment programme in Thyolo district, Malawi Southern Region. MSF Luxembourg & Thyolo District Health Services - Strategic information.
Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Accumulation of Protease Mutations Among Patients on Non-Suppressive 2 nd -Line ART in Nigeria H. Rawizza, B. Chaplin, S. Meloni, P. Okonkwo, P. Kanki.
Dr. Prosper Chonzi MBChB, MPH, MBA Director of Health Harare City 30 November 2015 Harare – A Fast Track City.
1 Uses of Data from the WHO HIV Drug Resistance Strategy: 1. Monitoring of HIVDR emerging in treated groups in sentinel ART clinics HIV Drug Resistance.
Evidence for optimizing highly active antiretroviral treatment (HAART) in Kenya Dr. Washingtone Ochieng CNHR RCDG Fellow returning from Harvard University,
Response to Antiretroviral Treatment In an Ethiopian Hospital Samuel Hailemariam, MD, MPH; J Allen McCutchan, MD, MSc Meaza Demissie, MD, PMH, PHD; Alemayehu.
THE ROLE OF TREATMENT LITERACY AND PLHIV EMPOWERMENT Lihle Dlamini (Treatment Action Campaign, South Africa):
ACTG 5142: First-line Antiretroviral Therapy With Efavirenz Plus NRTIs Has Greater Antiretroviral Activity Than Lopinavir/Ritonavir Plus NRTIs Slideset.
1 Predictors of Immunological Failure Among Adult Patients Receiving ART at an urban, HIV Clinic in Uganda Dr. Muhumuza Simon (M.D, MPH) Mulago-Mbarara.
HIV Drug Resistance Surveillance Satellite Session: HIV Drug Resistance Surveillance and Control: a Global Concern Silvia Bertagnolio, MD WHO,
Joseph Kibachio4, William Etienne1, Saar Baert5, Helen Bygrave5
PRE-EXPOSURE PROPHYLAXIS in Pregnancy in South Africa
Learning objectives Review HIV treatment goals
Learning objectives Define HIV treatment goals
How differentiated care supports “Tx all” and Dr
Alarming rates of virological failure and drug resistance in patients on long-term antiretroviral treatment in routine HIV clinics in Togo. Abla A. KONOU,
Figure 1 Inclusion criteria, exclusion criteria, and criteria for virologic failure. CDC, Centers for Disease Control and Prevention; ddC, zalcitabine;
Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort.
Background Results Methods Conclusion
Jeopardy Game Hosted by PHDP Jamaica MODULE 4 Treatment Literacy.
Introduction Results Objectives Methods Conclusion Funding
Madisa Mine National Health Laboratory Gaborone, BOTSWANA
Utilizing research as an opportunity to strengthen
New regimen for $75 a year New pricing agreement will speed up access to generic, dolutegravir (DTG)-based fixed dose combinations (FDCs)  HIV positive.
World Epidemiology. Are HIV and Other Chronic Diseases Models Applicable to Viral Hepatitis? Focus on HCV.
International AIDS Economics Network (IAEN) Conference
EVALUATION OF ANTIRETROVIRAL THERAPY FOLLOWED BY AN EDUCATIONAL INTERVENTION TO INCREASE APPROPRIATE USE IN ZIMBABWE.
Serge Masyn Director, Johnson & Johnson Global Public Health
From toward HIV Elimination with Boosted-Integrated Active HIV Case Management (B-IACM) in Cambodia Dr. Penh Sun LY, Director, NCHADS Presented.
Our Strategies for Viral Load Suppression
Paul De Lay Director, Evaluation UNAIDS
Type your title here Type author Names here *Affiliation 1
Title Goes Here Title Goes Here Title Goes Here Title Goes Here
EAC for children.
Silvia Bertagnolio, MD HIV Department World Health Organization
Update on global progress in ART
For a healthy Zambia.
Share your thoughts on this presentation with #IAS2019
Presentation transcript:

Summary Slide Presentation Principles of HIV drug resistance for clinical management in South Africa Stott K, Michel J, de Oliveira T. Principles of HIV drug resistance for clinical management in South Africa HIV Nursing Matters,3(4):46-51 (2012).

Introduction This article reviews the South African guidelines for viral load monitoring and regimen switch and introduces basic concepts of drug resistance for nurses and health care workers. The information presented here is useful to practitioners throughout Southern Africa as most HIV epidemics in the region are dominated by the same HIV subtype (HIV-1 subtype C), and drug resistance develops by similar mechanisms. Reference: Stott K, Michel J, de Oliveira T. Principles of HIV drug resistance for clinical management in South Africa. HIV Nursing Matters,3(4):46-51 (2012).

Table 1: South African National Guidelines 2010, 3:19 Reference: Stott K, Michel J, de Oliveira T. Principles of HIV drug resistance for clinical management in South Africa. HIV Nursing Matters,3(4):46-51 (2012).

Table 2: Introduction on HIV-1 drug resistance mutations to first line ART in South Africa and its effects on other ARVs Reference: Stott K, Michel J, de Oliveira T. Principles of HIV drug resistance for clinical management in South Africa. HIV Nursing Matters,3(4):46-51 (2012).

Table 3: Example of an SATuRN RegaDB HIV-1 genotypic resistance test report. Reference: Stott K, Michel J, de Oliveira T. Principles of HIV drug resistance for clinical management in South Africa. HIV Nursing Matters,3(4):46-51 (2012).

Conclusion Drug resistance testing is not currently available in the public sector in most provinces of South Africa. However, with the recent publication of guidelines by the SA HIV Clinicians Society, it is hoped that drug resistance testing will become more widely available in the near future. In the meanwhile, attention must be focused on frequent, proactive monitoring for treatment failure. Patients with treatment failure should be supported with intensified adherence support, in conjunction with the correct application of criteria for regimen switching. This will reduce the amount of time that patients spend on failing regimens and limit the development of complex resistance patterns, encouraging a durable treatment response. Reference: Stott K, Michel J, de Oliveira T. Principles of HIV drug resistance for clinical management in South Africa. HIV Nursing Matters,3(4):46-51 (2012).

Open Access Article Stott K, Michel J, de Oliveira T. Principles of HIV drug resistance for clinical management in South Africa HIV Nursing Matters,3(4):46-51 (2012). Corresponding Author: Dr. Katharine Sott